View our archive of investor presentations, annual and interim reports from 4D pharma plc (AIM: DDDD)


Management presentation, October 2020

Developing Science, Delivering Therapies


KOL Event: MRx0518 SITC 2020 data, 11 November 2020

On Wednesday 11 November 13:00 GMT (08:00 ET), 4D pharma CEO Duncan Peyton and CSO Alex Stevenson are joined by Dr Mark P Lythgoe, Academic Clinical Fellow in Medical Oncology and Pharmacist at Imperial College London, and Dr Shubham Pant, Associate Professor Department of Investigational Cancer Therapeutics and Department of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, to discuss immuno-oncology LBP MRx0518 monotherapy and checkpoint inhibitor combination data published at SITC 2020.

To replay the call, visit https://wsw.com/webcast/cc/dddd.l/ and you can download the accompanying slides here.


R&D Webinar: Blautix® BHT-II-002 IBS Phase II, 7 October 2020

CSO Dr. Alex Stevenson discusses the results of the BHT-II-002 Phase II trial of Live Biotherapeutic Blautix for the treatment of both IBS-C and IBS-D. He is joined by CEO Duncan Peyton, and CBO Glenn Dourado. Followed by analyst Q&A session.

View the webinar below, and download the presentation slides and a transcript


R&D Webinar: MicroRx® platform, 1 September 2020

4D pharma's Research Director Dr Imke Mulder hosts a webinar discussing 4D's world-leading Live Biotherapeutic discovery platform MicroRx®. Imke is joined by Alex Stevenson, CSO, and senior members of the Research team. The presentation is followed by a Q&A session with analysts

View the webinar below, and download the presentation slides and a transcript of the audio



R&D Webinar Clinical Update: Oncology & COVID-19, 5 June 2020

4D's Chairman, CEO and CSO host a virtual R&D event providing an update on the Company's clinical programmes in oncology and COVID-19, including a Q&A with covering analysts

You can download the presentation slides and a transcript of the audio

Chardan's 2nd Annual Microbiome Medicine Summit, 17 March 2020

CEO Duncan Peyton and CSO Alex Stevenson provide an update on clinical progress in oncology, and timelines and catalysts for 2020



View RNS announcements

Subscribe to RNS email alerts


Date 2020 Sep 30
Title Interim results for the period ended 30 June 2020
Document (468KB)
Link
Date 2020 Jun 05
Title Annual report for the year ended 31 December 2019
Document (3,289KB)
Link
Date 2019 Sep 30
Title Interim results for the period ended 30 June 2019
Document (629KB)
Link
Date 2019 May 28
Title Annual report for the year ended 31 December 2018
Document (4,255KB)
Link
Date 2018 Sep 28
Title Interim results for the period ended 30 June 2018
Document (269KB)
Link visit
Date 2018 Apr 25
Title Annual report for the year ended 31 December 2017
Document (1,369KB)
Link
Date 2017 Sep 27
Title Interim results for the period ended 30 June 2017
Document (2,820KB)
Link
Date 2017 May 02
Title Annual report for the year ended 31 December 2016
Document (3,262KB)
Link
Date 2016 Sep 30
Title Interim results for the period ended 30 June 2016
Document
Link visit
Date 2016 May 06
Title Annual report for the year ended 31 December 2015
Document (771KB)
Link
Date 2015 Sep 29
Title Interim results for the period ended 30 June 2015
Document (429KB)
Link
Date 2015 May 06
Title Annual Report for the year ended 31 December 2014
Document (659KB)
Link
Date 2014 Sep 23
Title Interim results for the period ended 30 June 2014
Document
Link visit

For any enquiries please contact ir@4dpharmaplc.com

BACK TO TOP